In addition, we first to date illustrated that the interactions between ERβ isoforms were associated with ERβ-mediated resistance to EGFR-TKIs and also explored the rationale for using EGFR-TKIs combined with fulvestrant in EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.